PATENT CLAIM ANALYSIS

Application Number: 16029352
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "174100"]

Abstract:
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Claim (Index 14):
The method of  claim 13 , wherein said anticancer agent is an antimetabolite, an inhibitor of topoisomerase I and II, an alkylating agent, a microtubule inhibitor, an antiandrogen agent, a GNRh modulator or mixtures thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15110685', '15793820', '15110690', '15849436', '15849470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7705005897806806
- 35 USC 102 Novelty (BERT): 0.5378909870186616
- Combined Prediction Score: 0.7472396295044788
- Mean Citation Score: 337.588756
- Max Citation Score: 377.97064
- Similarity Product: 362.78131365649216

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test